Search Within

Weisheng Xu

Formats
  1. Journal Article (9)
  2. Meeting Abstract (4)
Groups
  1. GSK Faculty (3)
  2. Adult Leukemia (2)
  3. Cell Biology Program Faculty (2)
  4. Center for Hematologic Malignancies (2)
  5. Sloan Kettering Institute Faculty (2)
  6. Department of Medicine (1)

More Groups

People
  1. Paul Marks (13)
  2. Lang Ngo (9)
  3. Gisela Venta-Perez (8)
  4. Milos Dokmanovic (5)
  5. Chang-Yun Gui (4)
  6. Raphael Parmigiani (3)

More People

Years
  1. 2009 (1)
  2. 2008 (1)
  3. 2007 (2)
  4. 2006 (2)
  5. 2005 (3)
  6. 2004 (3)

More Years

Publications
  1. Cancer Research (5)
  2. Proceedings of the National Academy of Sciences of the United States of America (5)
  3. Journal of Cellular Biochemistry (1)
  4. Molecular Cancer Therapeutics (1)
  5. Oncogene (1)
Publishers
  1. American Association for Cancer Research (6)
  2. National Academy of Sciences (5)
  3. John Wiley & Sons (1)
  4. Nature Publishing Group (1)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Histone deacetylase inhibitors: Potential in cancer therapy
    Journal Article

    Marks, P. A.; Xu, W. S.
    Journal of Cellular Biochemistry (2009)

    Fulltext@MSK | Save
  • HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
    Journal Article

    Parmigiani, R. B.; Xu, W. S.; Venta-Perez, G.; Erdjument-Bromage, H.; Yaneva, M.; Tempst, P.; Marks, P. A.
    Proceedings of the National Academy of Sciences of the United States of America (2008)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitors: Molecular mechanisms of action
    Journal Article

    Xu, W. S.; Parmigiani, R. B.; Marks, P. A.
    Oncogene (2007)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitors selectively suppress expression of HDAC7
    Journal Article

    Dokmanovic, M.; Perez, G.; Xu, W.; Ngo, L.; Clarke, C.; Parmigiani, R. B.; Marks, P. A.
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • Role of pro- and anti-apoptotic proteins in prostate cancer cells sensitive and resistant to histone deacetylase inhibiton induced cell death
    Meeting Abstract

    Xu, W.; Ngo, L.; Perez, G.; Dokmanovic, M.; Marks, P. A.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
    Journal Article

    Xu, W.; Ngo, L.; Perez, G.; Dokmanovic, M.; Marks, P. A.
    Proceedings of the National Academy of Sciences of the United States of America (2006)

    Fulltext@MSK | Save
  • Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitor
    Meeting Abstract

    Ungerstedt, J. S.; Sowa, Y.; Xu, W.; Shao, Y.; Dokmanovic, M.; Perez, G.; Ngo, L.; Holmgren, A.; Jiang, X.; Marks, P. A.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Induction of polyploidy by histone deacetylase inhibitor: A pathway for antitumor effects
    Journal Article

    Xu, W. S.; Perez, G.; Ngo, L.; Gui, C. Y.; Marks, P. A.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
    Journal Article

    Ungerstedt, J. S.; Sowa, Y.; Xu, W. S.; Shao, Y.; Dokmanovic, M.; Perez, G.; Ngo, L.; Holmgren, A.; Jiang, X.; Marks, P. A.
    Proceedings of the National Academy of Sciences of the United States of America (2005)

    Fulltext@MSK | Save
  • Induction of mitotic defect is a novel anti-tumor mechanism of histone deacetylase inhibitor suberoylanilide hydroxamic acid
    Meeting Abstract

    Xu, W.; Perez, G.; Gui, C.; Thapi, D.; Ngo, L.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.
    Cancer Research (2004)

    Fulltext@MSK | Save